● Recruiting

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

Condition: Hepatic Impairment · Sponsor: Eisai Co., Ltd.

PhasePhase 1

Planned participants18

Who can joinAll sexes, 20 Years to 79 Years

Healthy volunteersYes

About this study

The primary purpose of the study is to evaluate the effects of mild and moderate hepatic impairment on PK of tasurgratinib after a single dose administration.

This description comes directly from the study's public registry record.

Talk to the study team

Inquiry Service. · eisai-chiken_hotline@hhc.eisai.co.jp

Always discuss trial participation with your own doctor first.

Locations (8)

Eisai Trial Site #6	Hakata, Fukuoka, Japan	Recruiting
Eisai Trial Site #4	Kurume, Fukuoka, Japan	Terminated
Eisai Trial Site #2	Yuhu, Oita Prefecture, Japan	Recruiting
Eisai Trial Site #3	Bukyo-ku, Tokyo, Japan	Recruiting
Eisai Trial Site #1	Mintato-ku, Tokyo, Japan	Recruiting
Eisai Trial Site #8	Shinjuku-ku, Tokyo, Japan	Recruiting
Eisai Trial Site #5	Kofu, Yamanashi, Japan	Recruiting
Eisai Trial Site #7	Kyoto, Japan	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04271488